Abstract
Evergreening or extension of drug life through various product life cycle management tactics is an issue that significantly affects the generic pharmaceutical sector. Evergreening results in delayed market access for generic companies as well as higher drug prices in market for a longer duration. Both of these results are detrimental to patients. This article looks at evergreening practices seen in various countries across the development index. It covers diverse countries on the development spectrum, ranging from countries like Canada and Australia to countries like India, Philippines and Thailand.It highlights the response that Governments and generic companies are taking to regulate and to counter ever-greening practices. The types of evergreening practices noted are follow-on or secondary patents, aggressive litigation practices, and fi nally patent mechanisms being linked with regulatory approval (linkage) introduced via Free Trade Agreements.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
